PMID- 33294298
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221116
IS  - 2162-2531 (Print)
IS  - 2162-2531 (Electronic)
IS  - 2162-2531 (Linking)
VI  - 22
DP  - 2020 Dec 4
TI  - miR-363 Alleviates Detrusor Fibrosis via the TGF-beta1/Smad Signaling Pathway by 
      Targeting Col1a2 in Rat Models of STZ-Induced T2DM.
PG  - 1142-1153
LID - 10.1016/j.omtn.2020.07.001 [doi]
AB  - Dysregulated expression of microRNAs (miRNAs or miRs) has been implicated in the 
      pathophysiology of type 2 diabetes mellitus (T2DM). However, their underlying 
      role in the complication of detrusor fibrosis remains poorly understood. 
      Therefore, this study aimed to examine the potential functional relevance of 
      miR-363 in detrusor fibrosis of rats with streptozotocin (STZ)-induced T2DM 
      through the predicted target gene collagen type I alpha 2 (Col1a2). 
      Immunohistochemical analysis found an increase in the positive expression of 
      collagen type III alpha 1 (Col3a1) and Col1a2 in detrusor tissues, where miR-363 
      expression was decreased. Next, gain- and loss-of-function experiments were 
      performed to clarify the effects of miR-363 and Col1a2 on the activities of 
      bladder detrusor cells. Of note, binding affinity between miR-363 and Col1a2 was 
      verified by a dual-luciferase reporter gene assay and RNA immunoprecipitation 
      (RIP) assay. Upregulated miR-363 inhibited Col1a2 expression, which led to 
      increased expression of B-cell lymphoma 2 (Bcl-2) and Smad7 and accelerated cell 
      viability, along with decreases in cell apoptosis and Col3a1, Bcl-2-associated X 
      protein (Bax), transforming growth factor (TGF)-beta1, and Smad4 expressions. In 
      conclusion, miR-363 upregulation reduces detrusor fibrosis in rats with 
      STZ-induced T2DM through suppression of the TGF-beta1/Smad signaling pathway by 
      targeting Col1a2. Therefore, our study provided further insights for the 
      development of new therapeutic targets for T2DM.
CI  - (c) 2020.
FAU - Li, Xue-Feng
AU  - Li XF
AD  - Department of Anesthesiology, China-Japan Union Hospital of Jilin University, 
      Changchun 130033, P.R. China.
FAU - Zhang, Shu-Hua
AU  - Zhang SH
AD  - Operation Room, China-Japan Union Hospital of Jilin University, Changchun 130033, 
      P.R. China.
FAU - Liu, Gui-Feng
AU  - Liu GF
AD  - Department of Radiology, China-Japan Union Hospital of Jilin University, 
      Changchun 130033, P.R. China.
FAU - Yu, Shao-Nan
AU  - Yu SN
AD  - Department of Radiology, China-Japan Union Hospital of Jilin University, 
      Changchun 130033, P.R. China.
LA  - eng
PT  - Journal Article
PT  - Retracted Publication
DEP - 20200710
PL  - United States
TA  - Mol Ther Nucleic Acids
JT  - Molecular therapy. Nucleic acids
JID - 101581621
EIN - Mol Ther Nucleic Acids. 2022 Sep 02;29:787. PMID: 36159588
RIN - Mol Ther Nucleic Acids. 2022 Oct 26;30:323. PMID: 36381575
PMC - PMC7695978
OTO - NOTNLM
OT  - Col1a2
OT  - TGF-beta1/Smad signaling pathway
OT  - detrusor fibrosis
OT  - microRNA-363
OT  - type 2 diabetes mellitus
EDAT- 2020/12/10 06:00
MHDA- 2020/12/10 06:01
PMCR- 2020/07/10
CRDT- 2020/12/09 06:14
PHST- 2020/06/10 00:00 [received]
PHST- 2020/07/06 00:00 [accepted]
PHST- 2020/12/09 06:14 [entrez]
PHST- 2020/12/10 06:00 [pubmed]
PHST- 2020/12/10 06:01 [medline]
PHST- 2020/07/10 00:00 [pmc-release]
AID - S2162-2531(20)30190-6 [pii]
AID - 10.1016/j.omtn.2020.07.001 [doi]
PST - epublish
SO  - Mol Ther Nucleic Acids. 2020 Jul 10;22:1142-1153. doi: 
      10.1016/j.omtn.2020.07.001. eCollection 2020 Dec 4.